semaglutide and mash As the role of #GLP1 therapies in #MASLD continues to grow, clinicians need clear guidance. A new Practice Guidance update in #HEPATOLOGY provides evidence-based recommendations on using therapy for MASH, including Semaglutide vs Resmetirom for MASH

in 2012 concluded that the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in patients with metastatic BRAF V600 melanoma, represents one strategy for delaying the emergence of this resistance mechanism (median duration of response for combination therapy 10.5 vs 5.6 months for dabrafenib monotherapy) [28]

Am Fam Physician

Research by Sedighi et al

The body enters a kind of metabolic emergency mode

Future efforts should focus on developing strategies to enable multi-drug encapsulation, enhance long-term stability, and personalize treatments based on patient-specific data

Long-acting sulfonylurea d